Cargando…

Adjuvant Systemic Anti-cancer Therapy in Early Breast Cancer During the COVID-19 Pandemic: Differences between Clinicians and Patients in Perception of Treatment Risks and Benefits

Detalles Bibliográficos
Autores principales:	Gatfield, E.R., Mukesh, M.B., Loo, S.W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Royal College of Radiologists. Published by Elsevier Ltd. 2020
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280104/ https://www.ncbi.nlm.nih.gov/pubmed/32536560 http://dx.doi.org/10.1016/j.clon.2020.06.001

Ejemplares similares

Assessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer
por: Möbus, Volker, et al.
Publicado: (2017)

Survey of clinicians on the use of adjuvant therapy for premenopausal women with breast cancer
por: Lee, Young-Won, et al.
Publicado: (2023)

Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer?
por: Alliot, C
Publicado: (2006)

Clinicians’ Perceptions of the Benefits and Challenges of Teleoncology as Experienced Through the COVID-19 Pandemic: Qualitative Study
por: Alpert, Jordan M, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
por: Tran, Phuong T., et al.
Publicado: (2020)

Chromosome instability and benefit from adjuvant anthracyclines in breast cancer
por: Munro, A F, et al.
Publicado: (2012)

Adjuvant tamoxifen for early breast cancer.
por: Smith, I.
Publicado: (1988)

Adjuvant chemotherapy for early breast cancer.
por: Henderson, I. C.
Publicado: (1990)

The clinician’s perspective on the 21-gene assay in early breast cancer
por: Cognetti, Francesco, et al.
Publicado: (2021)

Update on Adjuvant Chemotherapy for Early Breast Cancer
por: Rampurwala, Murtuza M, et al.
Publicado: (2014)

Bisphosphonates in the adjuvant treatment of early breast cancer
por: Gnant, M
Publicado: (2009)

Adjuvant Breast Radiotherapy at an Academic Centre during the COVID-19 Pandemic: Reassuringly Safe
por: Hanumanthappa, N., et al.
Publicado: (2021)

Adherence to Adjuvant Hormonal Therapy and Associated Factors Among Women with Breast Cancer [Letter]
por: Bekele, Firomsa
Publicado: (2021)

S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer.
por: Stål, O., et al.
Publicado: (1994)

Incidence of metabolic syndrome in breast cancer survivors on adjuvant hormonal therapy
por: Kate, Anahita, et al.
Publicado: (2016)

Wait-time for adjuvant radiotherapy and oncologic outcome in early-stage cervical cancer: A treatment implication during the coronavirus pandemic
por: Matsuo, Koji, et al.
Publicado: (2021)

Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients
por: de Boo, Leonora W., et al.
Publicado: (2022)

Editorial: Risks and Benefits of Adjuvants to Cancer Therapies
por: Dong, Peixin, et al.
Publicado: (2022)

Association of Adjuvant Chemotherapy With Overall Survival in Patients With Early-Stage Breast Cancer and 21-Gene Recurrence Scores of 26 or Higher
por: Ma, Sung Jun, et al.
Publicado: (2020)

Patients' and Clinicians' Perceptions of Clinician-Expressed Empathy in Advanced Cancer Consultations and Associations with Patient Outcomes
por: Hoffstädt, Hinke, et al.
Publicado: (2020)

A Risk-benefit Assessment Approach to Selection of Adjuvant Chemotherapy in Elderly Patients with Early Breast Cancer: A Mini Review
por: Agarwala, Vivek, et al.
Publicado: (2017)

Adjuvant chemotherapy could benefit early-stage ER/PR positive mucinous breast cancer: A SEER-based analysis
por: Gao, Hong-Fei, et al.
Publicado: (2020)

Adjuvant treatment in colorectal cancer
por: Taal, B G, et al.
Publicado: (2002)

Adjuvant endocrine therapy for premenopausal women with early breast cancer
por: Bao, Ting, et al.
Publicado: (2007)

Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment
por: Ribeiro, J., et al.
Publicado: (2013)

Current treatment of early breast cancer: adjuvant and neoadjuvant therapy
por: Miller, Elizabeth, et al.
Publicado: (2014)

Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK
por: Earl, H.M., et al.
Publicado: (2021)

Research Status of Systemic Adjuvant Therapy for Early Breast Cancer
por: Hu, Wenyu, et al.
Publicado: (2023)

Critical Care Clinician Wellness during the COVID-19 Pandemic: A Longitudinal Analysis
por: Kerlin, Meeta Prasad, et al.
Publicado: (2022)

Estimate of benefit attributable to wearing masks in Chicago during the early days of the pandemic
por: Retzinger, Damien G., et al.
Publicado: (2021)

Do we need biomarkers to predict the benefit of adding adjuvant taxanes for treatment of breast cancer?
por: Pérez-García, José, et al.
Publicado: (2012)

Co‐benefits and ‘no regrets’ benefits of influenza pandemic planning
por: Wilson, Nick, et al.
Publicado: (2010)

Patient‐Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia
por: El‐Jawahri, Areej, et al.
Publicado: (2018)

Objective, Clinician- and Patient-Reported Evaluation of Late Toxicity Following Adjuvant Radiation for Early Breast Cancer: Long-Term Follow-Up Results of a Randomised Series
por: Dejonckheere, Cas Stefaan, et al.
Publicado: (2023)

Aspirin as adjuvant therapy in childhood cancer?
por: Morgan, G
Publicado: (2012)

The role of physical and rehabilitation medicine in the COVID-19 pandemic: The clinician's view
por: Carda, Stefano, et al.
Publicado: (2020)

Adjuvant! Online or comprehensive geriatric assessment for women over 70 years with primary breast cancer?
por: Monfardini, S, et al.
Publicado: (2012)

Adherence to Adjuvant Hormonal Therapy and Associated Factors Among Women with Breast Cancer [Response To Letter]
por: Wako, Zerko, et al.
Publicado: (2022)

Clinician's Perception of Practice Changes for Stroke During the COVID-19 Pandemic
por: Kamdar, Hera A., et al.
Publicado: (2020)

Managing bone health in women with breast cancer under adjuvant treatment with aromatase inhibitors: pretreatment bone mineral density is important
por: Markopoulos, Christos
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_etmbbfs9sq4i8o0vas2cbi9k7j